Summary
A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with IIIo AV block, severe hypotension, and impairment of ventricular function. One week prior to admission a therapy with standard doses of metoprolol (100 mg t.i.d. and then 100 mg b.i.d.) had been initiated. Two days before admission diltiazem (60 mg b.i.d.) was prescribed in addition. Analyses of a blood sample revealed unusually high plasma concentrations of metoprolol (> 3000 ng/ml) and diltiazem (526 ng/ml). The patient recovered within 1 week following discontinuation of antianginal therapy. Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism). It was found that he was a poor metabolizer of all four drugs, indicating that their metabolism is under the same genetic control. Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience adverse drug reactions when treated with standard doses of one of these drugs alone. Moreover, the coadministration of these frequently used drugs is expected to be especially harmful in this subgroup of patients.
Similar content being viewed by others
Abbreviations
- AUC :
-
area under the plasma concentration-time curve
- Cl :
-
clearance
- C max :
-
maximal plasma concentration
- EM :
-
extensive metabolizer
- F :
-
systemic availability
- PM :
-
poor metabolizer
- t 1/2:
-
half-life in plasma
- t max :
-
time to maximal plasma concentration
References
Briant RH, Dorrington RE, Ferry DG, Paxton JW (1983) Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine. Eur J Pharmacol 25:353–356
Brode E, Sachse R, Hoffmann HD (1982) Untersuchungen zur Analytik von Propafenon mittels interner Analogstan-dardisierung. Arzneim Forsch (Drug Res) 32:1–6
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183–187
Eichelbaum M, Reetz KP, Schmidt EK, Zekorn C (1986) The genetic polymorphism of sparteine metabolism. Xenobiotica 16:465–481
Goebel KJ, Kölle EU (1985) High-performance liquid chromatographic determination of diltiazem and four of its metabolites in plasma. J Chromatogr 345:355–363
Hollmann M, Brode E, Hotz D, Kaumeier S, Kehrhahn OH (1983) Investigations on the pharmacokinetics of propafenone in man. Arzneim Forsch (Drug Res) 33:763–770
Kirch W, Ohnhaus EE, Zekorn C, Eichelbaum M, Spahn H, Mutschler E (1985) Pharmacokinetics of metoprolol in relation to polymorphic sparteine oxidation. Arch Toxicol [Suppl] 8:401–402
Kölle EU, Ochs HR, Vollmer KO (1983) Pharmacokinetic model of diltiazem. Arzneim Forsch (Drug Res) 33:972–977
Lennard MS, Silas HJ, Freestone S, Ramsay LE, Tucker GT (1982) Oxidation phenotype-major determinant of metoprolol metabolism and response. N Engl J Med 307:1558–1560
Lennard MS, Tucker GT, Woods HF (1986) The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet 11:1–17
Piepho RW, Bloedow DC, Lacz JP, Ranser DJ (1982) Pharmacokinetics of diltiazem in selected animal species and man. Am J Cardiol 49:525–528
Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Woosley RL (1987) Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75:785–791
Trenk D, Wagner F, Jähnchen E, Eichelbaum M, Zekron C, Harnasch P, Hauf G, Roskamm H (1987) Genetischer Polymorphismus des Propafenon-Metabolismus. Z Kardiol [Suppl 1] 76:81
Wagner F, Kalusche D, Trenk D, Jähnchen E, Roskamm H (1987) Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol 24:213–220
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wagner, F., Jähnchen, E., Trenk, D. et al. Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine. Klin Wochenschr 65, 1164–1168 (1987). https://doi.org/10.1007/BF01733250
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01733250